Earnings ·
Cerus Corporation reported second quarter 2026 financial results with total revenue of $63.3 million, a 5% increase…
CERSCerus Corp
Cerus Corporation reported second quarter 2026 financial results with total revenue of $63.3 million, a 5% increase year-over-year, driven by a 10% rise in product revenue to $57.4 million. The company raised its full-year 2026 product revenue guidance to $229–$231 million and increased its IFC sales outlook to $23–$25 million. Cerus completed a debt refinancing, reducing the term loan by $30 million using cash on hand and new borrowings under a lower-cost facility. Additionally, the company expanded its BARDA collaboration, increasing the contract's total potential value by $21.9 million to $270.5 million. Cerus Corporation develops pathogen reduction technologies and blood safety products for hospitals and blood centers.